Page last updated: 2024-10-30

mepivacaine and Urinary Retention

mepivacaine has been researched along with Urinary Retention in 5 studies

Mepivacaine: A local anesthetic that is chemically related to BUPIVACAINE but pharmacologically related to LIDOCAINE. It is indicated for infiltration, nerve block, and epidural anesthesia. Mepivacaine is effective topically only in large doses and therefore should not be used by this route. (From AMA Drug Evaluations, 1994, p168)
mepivacaine : A piperidinecarboxamide in which N-methylpipecolic acid and 2,6-dimethylaniline have combined to form the amide bond. It is used as a local amide-type anaesthetic.

Urinary Retention: Inability to empty the URINARY BLADDER with voiding (URINATION).

Research Excerpts

ExcerptRelevanceReference
"We report a patient in whom urinary retention as a transient neurologic symptoms (TNS) developed after accidental total spinal anesthesia with mepivacaine hydrochloride."7.70[Urinary retention as a transient neurologic symptom after accidental total spinal anesthesia with mepivacaine hydrochloride]. ( Adachi, Y; Sato, T; Uchihashi, Y; Watanabe, K, 1999)
"We report a patient in whom urinary retention as a transient neurologic symptoms (TNS) developed after accidental total spinal anesthesia with mepivacaine hydrochloride."3.70[Urinary retention as a transient neurologic symptom after accidental total spinal anesthesia with mepivacaine hydrochloride]. ( Adachi, Y; Sato, T; Uchihashi, Y; Watanabe, K, 1999)

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (20.00)18.2507
2000's0 (0.00)29.6817
2010's2 (40.00)24.3611
2020's2 (40.00)2.80

Authors

AuthorsStudies
Stenmark, F2
Brudin, L2
Kjölhede, H1
Peeker, R2
Stranne, J2
Slaven, SE1
Dedeogullari, ES1
Parks, NL1
Sershon, RA1
Fricka, KB1
Hamilton, WG1
Mahan, MC1
Jildeh, TR1
Tenbrunsel, TN1
Davis, JJ1
Adachi, Y1
Watanabe, K1
Uchihashi, Y1
Sato, T1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Randomized, Controlled, Double-Blind Trial of 3 Local Anesthetics for Spinal Anesthesia in Primary Total Hip Arthroplasty to Compare the Percentage of Patients in Each Group With Early Ambulation[NCT03948386]Phase 4159 participants (Actual)Interventional2019-05-13Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Hospital Stay

length of hospital stay (NCT03948386)
Timeframe: hospital stay (0-3 days)

Interventionhours (Median)
Isobaric Bupivacaine26
Hyperbaric Bupivacaine26
Isobaric Mepivacaine22

Number of Patients With Dizziness Events

number of patients with dizziness when transitioning from lying down to sitting or standing (NCT03948386)
Timeframe: Postoperative day 2

InterventionParticipants (Count of Participants)
Isobaric Bupivacaine11
Hyperbaric Bupivacaine7
Isobaric Mepivacaine9

Number of Patients With Transient Neurological Symptoms (TNS)

Number of patients with TNS events occurring. Transient neurological symptoms were defined as new onset of back, buttock, or thigh pain occurring after spinal anesthesia. (NCT03948386)
Timeframe: Postoperative days 0-2

InterventionParticipants (Count of Participants)
Isobaric Bupivacaine2
Hyperbaric Bupivacaine6
Isobaric Mepivacaine5

Number of Patients With Urinary Retention Events

number of patients with inability to urinate within 8 hours of surgery OR a report of distended or painful bladder occurring on postoperative day 0 or 1, either by patient report or on palpation by nursing (NCT03948386)
Timeframe: postoperative day 1

InterventionParticipants (Count of Participants)
Isobaric Bupivacaine6
Hyperbaric Bupivacaine8
Isobaric Mepivacaine5

Percentage Ambulating Early After Spinal Anesthesia

Is there a difference between isobaric mepivacaine, hyperbaric bupivacaine, and isobaric bupivacaine when used for spinal anesthesia in primary total hip replacement in percentage of patients that can ambulate within 3.5 hours after spinal anesthesia? (NCT03948386)
Timeframe: 3.5 hours

InterventionParticipants (Count of Participants)
Isobaric Bupivacaine9
Hyperbaric Bupivacaine20
Isobaric Mepivacaine35

Return of Motor Function of the Thigh and Lower Leg

time to return of motor function of the thigh and lower leg (NCT03948386)
Timeframe: Postoperative day 0 (day of surgery)

Interventionminutes (Median)
Isobaric Bupivacaine148
Hyperbaric Bupivacaine123
Isobaric Mepivacaine109

Other Studies

5 other studies available for mepivacaine and Urinary Retention

ArticleYear
Treatment with CoreTherm in 570 patients with prostate volumes of 80-366 ml: an evaluation of short- and long-term retreatment risk.
    Scandinavian journal of urology, 2022, Volume: 56, Issue:4

    Topics: Epinephrine; Humans; Male; Mepivacaine; Prostate; Prostatic Hyperplasia; Retreatment; Transurethral

2022
Spinal Anesthesia for Primary Hip and Knee Arthroplasty: Comparative Rates of Transient Neurological Symptoms and Urinary Retention Using Lidocaine, Mepivacaine, and Bupivacaine.
    The Journal of arthroplasty, 2023, Volume: 38, Issue:6S

    Topics: Anesthesia, Spinal; Anesthetics, Local; Arthroplasty, Replacement, Knee; Bupivacaine; Humans; Lidoca

2023
Mepivacaine Spinal Anesthesia Facilitates Rapid Recovery in Total Knee Arthroplasty Compared to Bupivacaine.
    The Journal of arthroplasty, 2018, Volume: 33, Issue:6

    Topics: Aged; Analgesics, Opioid; Anesthesia, General; Anesthesia, Spinal; Anesthetics, Local; Arthroplasty,

2018
High-energy feedback microwave thermotherapy and intraprostatic injections of mepivacaine and adrenaline: an evaluation of calculated cell kill accuracy and responder rate.
    Scandinavian journal of urology, 2014, Volume: 48, Issue:4

    Topics: Aged; Aged, 80 and over; Cell Death; Combined Modality Therapy; Drug Therapy, Combination; Epinephri

2014
[Urinary retention as a transient neurologic symptom after accidental total spinal anesthesia with mepivacaine hydrochloride].
    Masui. The Japanese journal of anesthesiology, 1999, Volume: 48, Issue:9

    Topics: Adult; Anesthesia, Epidural; Anesthesia, Spinal; Anesthetics, Local; Diazepam; Female; Humans; Mepiv

1999